Synthesis and anti-HIV activity of novel cyclopentenyl nucleoside analogues of 8-azapurine

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 10, 2006, Pages 1418-1420

  Canoa, Pilar ^a   González Moa, María J ^a   Teijeira, Marta ^a   Terán, Carmen ^a   Uriarte, Eugenio ^b   Pannecouque, Christophe ^c   De Clercq, Erik ^c  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

8 azapurine derivative; Anti HIV activity; Carbocyclic nucleoside

Indexed keywords

2 AMINO 3 CYCLOPENTENYLMETHANOL; 2 AMINO 8 AZA 6 CHLORO 9 (2 HYDROXYMETHYL 4 CYCLOPENTENYL)PURINE; 2 AMINO 8 AZA 6 HYDROXY 9 (2 HYDROXYMETHYL 4 CYCLOPENTENYL)PURINE; 2,6 DIAMINO 8 AZA 9 (2 HYDROXYMETHYL 4 CYCLOPENTENYL)PURINE; 8 AZAPURINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHLORINE DERIVATIVE; CYCLOPENTENYL NUCLEOSIDE DERIVATIVE; METHANOL DERIVATIVE; NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IC 50; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; CYCLOPENTANES; HIV-1; HIV-2; HUMANS; METHANOL; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NUCLEOSIDES; PURINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 33749385788     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.1418     Document Type: Article

References (14)

1. Mitsuya H., "Anti-HIV Nucleosides: Past, Present and Future," Chap. 1, Springer-Verlag, Heidelberg, 1997.
2. Simons C., "Nucleoside Mimetics Their Chemistry and Biological Properties," Chap. 1, Gordon and Breach Science Publishers, Amsterdam, 2001.
3. Marquez V., "Advances in Antiviral Drug Design," Vol. 2, ed. by De Clercq E., JAI Press, Greenwich, 1996, pp. 89-146.
4. Agrofoglio L. A., Challand S. R., "Acyclic, Carbocyclic and L-Nucleosides," Chap. 3, Klumer Academis Publishers, Dordrecht, 1998.
5. Tan X., Chu Ch. K., Boudinot F. D., Adv. Drug Deliv. Rev., 39, 117-151 (1999).
6. De Clercq E., Chemistry Biodiversity, 1, 44-64 (2004).
7. Daluge S. M., Good S. S., Faletto M. B., Miller W. H., St. Clair M. H., Boone L. R., Tisdale M., Parry N. R., Reardon J. E., Dornsife R. E., Averett D. R., Krenitsky J. A., Antimicrob. Agents Chemother., 41, 1082-1093 (1997).
8. Holy A., Dvoráková H., Jindrich J., Masojídkova M., Budesinsk M., Balzarini J., Andrei G., De Clercq E., J. Med. Chem., 39, 4073-4088 (1996).
9. Santana L., Teijeira M., Uriarte E., Balzarini J., De Clercq E., Bioorg. Med. Chem. Lett., 8, 1349-1352 (1998).
10. Estrada E., Uriarte E., Montero A., Teijeira M., Santana L., De Clercq E., J. Med. Chem., 43, 1975-1985 (2000).
11. Besada P., González-Moa M. J., Terán C., Santana L., Uriarte E., Synthesis, 2002, 2445-2449 (2002).
12. Beauchamp L. M., Dolmatch B. L., Schaeffer H. J., Collins P., Bauer D. J., Keller P. M., Fyfe J. A., J. Med Chem., 28, 982-987 (1985).
13. Havlicek L., Fuksova K., Krystof V., Orsag M., Vojtesek B., Strnad M., Bioorg. Med. Chem. Lett., 13, 5399-5407 (2005).
14. Pauwels R., De Clercq E., Desmyter J., Balzarini J., Goubau P., Herdewijn P., Vanderhaeghe H., Vandeputte M., J. Virol. Methods, 16, 171-185 (1987).